Genus plc (LON:GNS)
London · Delayed Price · Currency is GBP · Price in GBX 2,162.00
+2.00 (0.09%)
Sep 11, 2026, 4:47 PM GMT
Genus Market Cap
Genus has a market cap or net worth of 1.45 billion as of September 11, 2026. Its market cap has decreased by -18.67% in one year.
Market Cap
1.45B
Enterprise Value
1.51B
Revenue
658.10M
Ranking
n/a
PE Ratio
5.08
Stock Price
2,162.00
ChartMarket Cap Chart
Since January 30, 1998, Genus's market cap has increased from 31.03M to 1.45B, an increase of 4,557.96%. That is a compound annual growth rate of 14.36%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 1.45B | -16.76% |
| Dec 31, 2025 | 1.74B | 70.54% |
| Dec 31, 2024 | 1.02B | -28.43% |
| Dec 29, 2023 | 1.42B | -27.10% |
| Dec 30, 2022 | 1.95B | -39.35% |
| Dec 31, 2021 | 3.22B | 18.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Oxford Nanopore Technologies | 1.54B |
| Oxford Biomedica | 537.41M |
| Avacta Group | 332.57M |
| PureTech Health | 293.56M |
| Scancell Holdings | 121.83M |
| Bioventix | 84.64M |
| 4basebio | 74.58M |
| Faron Pharmaceuticals Oy | 72.29M |